Copyright © 1992 by the European Society of Cardiology.
© 1992 The European Society of Cardiology
The potential role of endothelin as a vasoconstrictor substance in congestive heart failure
From the Division of Cardiology, Department of Medicine, The Ohio State University College of Medicine and Hospitals Columbus, Ohio, U.S.A.
Received 20 June 1992; .
Correspondence: Robert J. Cody, MD, Division of Cardiology, 611 Means Hall, The Ohio State University Hospitals, 1654 Upham Drive, Columbus, OH 43210, U.S.A.
Abstract
A rapidly growing body of data supports the concept of in situ regulation of vascular tone: the ability of vasoactive substances to regulate vascular tone at their site of production within the wall of the vasculature. Sufficient data exist to suggest that ineffective production or response to endothelium-dependent vasodilator substances, or excessive production or responsiveness to endothelium-dependent vasoconstrictor substances may play an important role in cardiovascular disorders such as hypertension, coronary artery spasm, restenosis following coronary angioplasty, and congestive heart failure. The present review summarizes data which support the concept that endothelin, a potent vasoconstrictor produced by the endothelium, may play a role in the excessive vasoconstriction of heart failure. Increased circulating plasma endothelin may be particularly relevant to the range of pulmonary vasoconstriction encountered in congestive heart failure, with a correlation revealing that the greatest increase of plasma endothelin occurs in patients with marked pulmonary hypertension within the congestive heart failure patients studied.
Key Words: Endothelin • neurohormones • heart failure • haemodynamics • pulmonary hypertension
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. T Goodwin, M. Amrani, A. J Marchbank, C. C Gray, J. Jayakumar, and M. H Yacoub Coronary vasoconstriction to endothelin-1 increases with age before and after ischaemia and reperfusion Cardiovasc Res, March 1, 1999; 41(3): 554 - 562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupuis, J.-L. Rouleau, and P. Cernacek Reduced Pulmonary Clearance of Endothelin-1 Contributes to the Increase of Circulating Levels in Heart Failure Secondary to Myocardial Infarction Circulation, October 20, 1998; 98(16): 1684 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T Goodwin, M. Amrani, C. C Gray, J. Jayakumar, and M. H Yacoub Role of endogenous endothelin in the regulation of basal coronary tone in the rat J. Physiol., September 1, 1998; 511(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, V. Richard, F. Bouchart, G. Derumeaux, K. Munter, and C. Thuillez Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure Cardiovasc Res, September 1, 1998; 39(3): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dupuis, G. W Moe, and P. Cernacek Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure Cardiovasc Res, September 1, 1998; 39(3): 609 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Knothe, J. Boldt, B. Zickmann, S. Konstantinov, P. Dick, F. Dapper, and G. Hempelmann Influence of different flow modi during extracorporeal circulation on endothelial-derived vasoactive substances Perfusion, July 1, 1995; 10(4): 229 - 236. [Abstract] [PDF]
|
|